Filtered By:
Drug: Rituxan
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 5018 results found since Jan 2013.
The Roles of Exosomal microRNAs in Diffuse Large B-Cell Lymphoma: Diagnosis, Prognosis, Clinical Application, and Biomolecular Mechanisms
DiscussionAccording to our systematic review, exosomal miRNAs are not only useful for diagnosis and prognosis in DLBCL but are also promising therapeutic tools and predictors of response to therapy. Although promising results so far, more research is required to develop innovative biomarkers.
Source: Frontiers in Oncology - June 2, 2022 Category: Cancer & Oncology Source Type: research
Refractory and relapsed hairy-cell leukemia (HCL): Casting light on promising experimental drugs in clinical trials
This article summarizes recent achievements in the treatment of relapsed and refractory HCL. A literature search was conducted of the PubMed and MEDLINE database for articles in English. Publications from 2010 through January 2023 were scrutinized. The search terms used were hairy cell leukemia in conjunction with BRAF inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, CD20 monoclonal antibodies, relapsed, refractory and variant.The growing understanding of HCL biology has allowed the design of several new, chemotherapy-free targeted drugs which have demonstrated encouraging efficacy in early clinical trials.EXPERT OPI...
Source: Expert Opinion on Investigational Drugs - March 17, 2023 Category: Drugs & Pharmacology Authors: Tadeusz Robak Pawe ł Robak Source Type: research
Risk factors for relapse in non-infectious cryoglobulinemic vasculitis, including type I cryoglobulinemia: a systematic review
ConclusionOur findings underscore the significance of attaining both clinical and immunological responses and identifying risk factors for relapse in NICV. Appropriate risk stratification for NICV patients is essential for the successful implementation of effective treatment strategies.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023408140.
Source: Frontiers in Immunology - July 7, 2023 Category: Allergy & Immunology Source Type: research
Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review
CONCLUSIONS: The use of SC daratumumab, rituximab, and trastuzumab in patients with cancer reduces direct and indirect costs and adverse events compared to IV use. Patients prefer the SC administration, perceiving more comfort, and less pain at the administration site.PMID:37665685 | DOI:10.1080/14737167.2023.2249232
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 4, 2023 Category: Health Management Authors: Ana Parra Claudia Hern ández Laura Prieto-Pinto Source Type: research
